Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas. This trial investigates the effect of concurrent and adjuvant temozolomide on health-related quality of life (HRQoL). Materials and methods: In this randomized, open-label, phase II trial, 90 patients with World Health Organization grade III glioma were enrolled across multiple centers in South Korea between March 2012 to February 2015 and followed up through 2017. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) and 20-item EORTC QLQ-Brain Neoplasm (QLQ-BN20) were used to compare HRQoL between patients assigned to concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A) and radiotherapy (RT) alone (arm B). Results: Of the 90 patients in the study, 84 patients (93.3%) completed the baseline HRQoL questionnaire. Emotional functioning, fatigue, nausea and vomiting, dyspnea, constipation, appetite loss, diarrhea, seizures, itchy skin, drowsiness, hair loss, and bladder control were not affected by the addition of temozolomide. All other items did not differ significantly between arm A and arm B throughout treatment. Global health status particularly stayed consistent at the end of adjuvant temozolomide (p=0.47) and at the end of RT (p=0.33). Conclusion: The addition of concurrent and adjuvant temozolomide did not show negative influence on HRQoL with improvement of progression-free survival for patients with anaplastic gliomas. The absence of systematic and clinically relevant changes in HRQoL suggests that an overall long-term net clinical benefit exists for concurrent and adjuvant temozolomide.
Abstract
Purpose: The KNOG-1101 study showed improved 2-year PFS with temozolomide during and after radiotherapy compared to radiotherapy alone for patients with anaplastic gliomas. This trial investigates the effect of concurrent and adjuvant temozolomide on health-related quality of life (HRQoL). Materials and methods: In this randomized, open-label, phase II trial, 90 patients with World Health Organization grade III glioma were enrolled across multiple centers in South Korea between March 2012 to February 2015 and followed up through 2017. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire 30 (EORTC QLQ-C30) and 20-item EORTC QLQ-Brain Neoplasm (QLQ-BN20) were used to compare HRQoL between patients assigned to concurrent chemoradiotherapy with temozolomide followed by 6 cycles of adjuvant temozolomide (arm A) and radiotherapy (RT) alone (arm B). Results: Of the 90 patients in the study, 84 patients (93.3%) completed the baseline HRQoL questionnaire. Emotional functioning, fatigue, nausea and vomiting, dyspnea, constipation, appetite loss, diarrhea, seizures, itchy skin, drowsiness, hair loss, and bladder control were not affected by the addition of temozolomide. All other items did not differ significantly between arm A and arm B throughout treatment. Global health status particularly stayed consistent at the end of adjuvant temozolomide (p=0.47) and at the end of RT (p=0.33). Conclusion: The addition of concurrent and adjuvant temozolomide did not show negative influence on HRQoL with improvement of progression-free survival for patients with anaplastic gliomas. The absence of systematic and clinically relevant changes in HRQoL suggests that an overall long-term net clinical benefit exists for concurrent and adjuvant temozolomide.
참고문헌 (28)
- Izquierdo C, "Anaplastic gliomas in adults : an update", Curr Opin Oncol, 29, pp.434~442 (2017)
- Siker ML, "Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma?", Crit Rev Oncol Hematol, 60, pp.99~111 (2006)
- Hegi ME, "MGMT gene silencing and benefit from temozolomide in glioblastoma", N Engl J Med, 352, pp.997~1003 (2005)
- Stupp R, "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study : 5-year analysis of the EORTC-NCIC trial", Lancet Oncol, 10, pp.459~466 (2009)
- Stupp R, "Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma", N Engl J Med, 352, pp.987~996 (2005)
- van den Bent MJ, "Interim results from the CATNON trial(EORTC study 26053-22054)of treatment with concurrent and adjuvant temozolomide for 1p", 19q non-co-deleted anaplastic glioma : a phase 3, randomised, open-label intergroup study, 2017, pp.390, 1645~1653
- Kim YH, "Temozolomide during and after radiation therapy for WHO grade III gliomas : preliminary report of a prospective multicenter study", J Neurooncol, 103, pp.503~512 (2011)
- Vogelbaum MA, "Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas : long term results of RTOG BR0131", J Neurooncol, 124, pp.413~420 (2015)
- BerghoffA, "How I treat anaplastic glioma without 1p", 19q codeletion, 2019, pp.4, e000534~
- Cairncross JG, "Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas", J Natl Cancer Inst, 90, pp.1473~1479 (1998)
- Hartmann C, "Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age : implications for classification of gliomas", Acta Neuropathol, 120, pp.707~718 (2010)
- Kamiryo T, "Correlation between promoter hypermethylation of the O6-methylguanine-deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy", Neurosurgery, 54, pp.349~357 (2004)
- Smith JS, "Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas", J Clin Oncol, 18, pp.636~645 (2000)
- Cairncross G, "Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma : long-term results of RTOG 9402", J Clin Oncol, 31, pp.337~343 (2013)
- van den Bent MJ, "Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma : long-term follow-up of EORTC brain tumor group study 26951", J Clin Oncol, 31, pp.344~350 (2013)
- 김창욱, "Health-Related Quality of Life in Brain Tumor Patients Treated with Surgery: Preliminary Result of a Single Institution", Brain Tumor Research and Treatment, 4(2), pp.87~93 (2016), 대한뇌종양학회
- 황기환, "Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p", 19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study), 2020, pp.52(2), 505~515[DOI]
- Jenkins RB, "Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group", Am J Clin Oncol, 24, pp.506~508 (2001)
- Walker MD, "Evaluation of BCNU and", or radiotherapy in the treatment of anaplastic gliomas : a cooperative clinical trial, 1978, pp.49, 333~343
- Walker MD, "Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery", N Engl J Med, 303, pp.1323~1329 (1980)
- DeAngelis LM, "Brain tumors", N Engl J Med, 344, pp.114~123 (2001)
- Simonetti G, "Update on treatment strategies for anaplastic glioma : a review of literature", Neurol Sci, 35, pp.977~981 (2014)
- Sasaki H, "Treatment recommendations for adult patients with diffuse gliomas of grades II and III according to the new WHO classification in 2016", Neurol Med Chir(Tokyo), 57, pp.658~666 (2017)
- Chibbaro S, "Temozolomide as first-line agent in treating high-grade gliomas : phase II study", J Neurooncol, 67, pp.77~81 (2004)
- 주진덕, "Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas : A Prospective Multicenter Study of Korean Patients", 대한신경외과학회지, 52(2), pp.92~97 (2012), 대한신경외과학회[DOI]
- 주진덕, "Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution", Journal of Korean Medical Science, 30(11), pp.1597~1603 (2015), 대한의학회
- 배소현, "Toxicity Profile of Temozolomide in the Treatment of 300 Malignant Glioma Patients in Korea", Journal of Korean Medical Science, 29(7), pp.980~984 (2014), 대한의학회
- Dirven L, "Health-related quality of life in high-grade glioma patients", Chin J Cancer, 33, pp.40~45 (2014)